Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) FCF Margin (2018 - 2025)

Serina Therapeutics (SER) has disclosed FCF Margin for 8 consecutive years, with 2941.54% as the latest value for Q2 2025.

  • Quarterly FCF Margin rose 1276238.0% to 2941.54% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 13891.54% through Dec 2025, up 1674953.0% year-over-year, with the annual reading at 13891.54% for FY2025, 1674953.0% up from the prior year.
  • FCF Margin hit 2941.54% in Q2 2025 for Serina Therapeutics, down from 32814.29% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 32814.29% in Q4 2024 to a low of 32720.0% in Q1 2022.
  • Historically, FCF Margin has averaged 9284.78% across 5 years, with a median of 7475.0% in 2021.
  • Biggest YoY gain for FCF Margin was 3281263bps in 2024; the steepest drop was -2945667bps in 2024.
  • Year by year, FCF Margin stood at 6100.0% in 2021, then crashed by -171bps to 16512.5% in 2022, then skyrocketed by 100bps to 1.65% in 2023, then skyrocketed by 1986129bps to 32814.29% in 2024, then crashed by -109bps to 2941.54% in 2025.
  • Business Quant data shows FCF Margin for SER at 2941.54% in Q2 2025, 32814.29% in Q4 2024, and 21178.57% in Q3 2024.